Algae Compound Promising for Alzheimer's

Cyanobacteria and other marine natural compounds have been increasingly demonstrated to be a promising source of drug candidates for combating a host of human diseases, including cancer and bacterial infections, but their chemistry has been largely unevaluated. Now, a common marine organism could lead to yet another potential health benefit, according to study leader Karl Gademann, Ph.D., an organic chemist at the Swiss Federal Institute of Technology (ETH) (Zürich, Switzerland; www.ethz.ch). Dr.Gademann's lab concentrates on identifying, synthesizing, and assessing new bioactive compounds from natural sources.

There is currently no cure for AD, although cholinesterase inhibitors have shown promise for delaying or preventing the symptoms of mild-to-moderate forms of the disease. The newly isolated compound, nostocarboline, has been shown to be a powerful suppressor of cholinesterase--a brain chemical believed to be critical for memory and thinking--whose breakdown has been associated with the disease's progression. The natural compound's potency is comparable to galanthamine, a cholinesterase inhibitor already approved for the treatment of Alzheimer's, according to the investigators.

As with any promising structure, it could be a long time before the new compound is tested as a drug candidate in humans, the scientists cautioned.





Related Links:
Swiss Federal Institute of Technology